Free tool
FAERS Monitor: Skyclarys
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216718 or its brand name (Skyclarys, Omaveloxolone). Reports on generic versions are filed under their own applications.
Reports
1,818
Serious
762
42% of reports
Hospitalization
451
Death reported
94
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue162
- nausea134
- hepatic enzyme increased130
- product dose omission issue107
- headache105
- diarrhoea95
- blood cholesterol increased86
- muscle spasms78
- fall76
- atrial fibrillation69
- alanine aminotransferase increased68
- death63
- urinary tract infection62
- abdominal pain upper60
- friedreich^s ataxia59
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 171 |
| 2024 | 665 |
| 2025 | 568 |
| 2026 | 414 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,341 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatic enzyme increasedSignal | 130 | 22.1 | 18.7 | 2,601 |
| blood cholesterol increasedSignal | 86 | 21.4 | 17.4 | 1,651 |
| alanine aminotransferase increasedSignal | 68 | 12.8 | 10.2 | 731 |
| atrial fibrillationSignal | 69 | 8.2 | 6.5 | 431 |
| muscle spasmsSignal | 78 | 4.9 | 4.0 | 242 |
| product dose omission issueSignal | 107 | 4.2 | 3.5 | 262 |
| urinary tract infectionSignal | 62 | 4.2 | 3.3 | 149 |
| abdominal pain upperSignal | 60 | 3.4 | 2.6 | 99 |
| fallSignal | 76 | 2.6 | 2.1 | 77 |
| fatigueSignal | 162 | 2.4 | 2.1 | 137 |
| nausea | 134 | 2.0 | 1.7 | 64 |
| headache | 105 | 1.9 | 1.6 | 48 |
| diarrhoea | 95 | 1.7 | 1.4 | 28 |
| death | 63 | 0.8 | 0.7 | 2 |
| friedreich^s ataxia | 59 | 0.0 | 0.0 | 671,687 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.